UOB Kay Hian lifted its target price for Ali Health (00241) to HK$21 from HK$17 and maintained its "buy" rating.
The research house has raised its FY21 revenue estimate by 9% to factor in the better performance in FY20 and large room for penetration in Alibaba's eco-system. It also raises its FY21 adj. net profit by 30%, considering Ali Health's proven ability in operation efficiency.
全新節目《說說心理話》青少年不可以戀愛!?真實個案講述驚心動魄經歷► 即睇